Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313597902> ?p ?o ?g. }
Showing items 1 to 99 of
99
with 100 items per page.
- W4313597902 endingPage "133" @default.
- W4313597902 startingPage "129" @default.
- W4313597902 abstract "Dual pathway inhibition (DPI) with low-dose rivaroxaban and aspirin in patients with coronary artery disease (CAD) and/or peripheral artery disease (PAD) reduces the occurrence of cardiovascular (CV) events; however, the underlying mechanisms explaining these latter CV benefits are not clearly understood. Our explorative observational study aimed to evaluate the effect of dual pathway inhibition on plasma inflammation and coagulation markers among real-world patients with CAD and/or PAD. We prospectively included all consecutive patients with an established diagnosis of CAD and/or PAD treated with aspirin 100 mg once daily (OD) and rivaroxaban 2.5 mg twice daily (TD). Clinical evaluation and laboratory analyses, including hemoglobin, renal function (creatinine, urea, and cystatin-C), coagulation markers (INR and aPTT), inflammation markers (IL-6, CRP, lipoprotein-associated phospholipase A2, and copeptin), and growth differentiation factor-15 (GDF-15), were conducted at baseline, before starting treatment, and at 4 and 24 weeks after study drug administration. Fifty-four consecutive patients (mean age 66 ± 7 years; male 83%) who completed the 6-month follow-up were included. At 24-week follow-up, a statistically significant reduction in IL-6 serum levels [4.6 (3.5-6.5) vs. 3.4 (2.4-4.3) pg/mL ; P = 0.0001] and fibrinogen [336 (290-390) vs. 310 (275-364) mg/dL; P = 0.04] was shown; moreover, a significant increase in GDF-15 serum level [1309 (974-1961) vs. 1538 (1286-2913) pg/mL; P = 0.002] was observed. Hemoglobin, renal function, and cardiovascular homeostasis biomarkers remain stable over the time. The anti-Xa activity at both [0.005 (0-0.02) vs. 0.2 (0.1-0.34); P < 0.0001) significantly increased. The dual pathway inhibitions with low-dose rivaroxaban and aspirin in patients with CAD and/or PAD were associated with the reduction of inflammation biomarkers." @default.
- W4313597902 created "2023-01-06" @default.
- W4313597902 creator A5003503228 @default.
- W4313597902 creator A5011873029 @default.
- W4313597902 creator A5012633824 @default.
- W4313597902 creator A5015966822 @default.
- W4313597902 creator A5025589047 @default.
- W4313597902 creator A5033587549 @default.
- W4313597902 creator A5034394063 @default.
- W4313597902 creator A5044656842 @default.
- W4313597902 creator A5050522038 @default.
- W4313597902 creator A5053841012 @default.
- W4313597902 creator A5058803497 @default.
- W4313597902 creator A5087804025 @default.
- W4313597902 date "2023-02-01" @default.
- W4313597902 modified "2023-10-16" @default.
- W4313597902 title "Dual Pathway Inhibition with Rivaroxaban and Aspirin Reduces Inflammatory Biomarkers in Atherosclerosis" @default.
- W4313597902 cites W2018619947 @default.
- W4313597902 cites W2073434079 @default.
- W4313597902 cites W2150179860 @default.
- W4313597902 cites W2548202628 @default.
- W4313597902 cites W2596497884 @default.
- W4313597902 cites W2749380187 @default.
- W4313597902 cites W2894869615 @default.
- W4313597902 cites W2989714602 @default.
- W4313597902 cites W3000897322 @default.
- W4313597902 cites W3044823137 @default.
- W4313597902 cites W3092527520 @default.
- W4313597902 cites W3197892150 @default.
- W4313597902 cites W4200209139 @default.
- W4313597902 cites W4223435170 @default.
- W4313597902 cites W4224324999 @default.
- W4313597902 cites W4283727253 @default.
- W4313597902 doi "https://doi.org/10.1097/fjc.0000000000001382" @default.
- W4313597902 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36607629" @default.
- W4313597902 hasPublicationYear "2023" @default.
- W4313597902 type Work @default.
- W4313597902 citedByCount "2" @default.
- W4313597902 countsByYear W43135979022023 @default.
- W4313597902 crossrefType "journal-article" @default.
- W4313597902 hasAuthorship W4313597902A5003503228 @default.
- W4313597902 hasAuthorship W4313597902A5011873029 @default.
- W4313597902 hasAuthorship W4313597902A5012633824 @default.
- W4313597902 hasAuthorship W4313597902A5015966822 @default.
- W4313597902 hasAuthorship W4313597902A5025589047 @default.
- W4313597902 hasAuthorship W4313597902A5033587549 @default.
- W4313597902 hasAuthorship W4313597902A5034394063 @default.
- W4313597902 hasAuthorship W4313597902A5044656842 @default.
- W4313597902 hasAuthorship W4313597902A5050522038 @default.
- W4313597902 hasAuthorship W4313597902A5053841012 @default.
- W4313597902 hasAuthorship W4313597902A5058803497 @default.
- W4313597902 hasAuthorship W4313597902A5087804025 @default.
- W4313597902 hasConcept C126322002 @default.
- W4313597902 hasConcept C159641895 @default.
- W4313597902 hasConcept C2776301958 @default.
- W4313597902 hasConcept C2776914184 @default.
- W4313597902 hasConcept C2777628954 @default.
- W4313597902 hasConcept C2778213512 @default.
- W4313597902 hasConcept C2778661090 @default.
- W4313597902 hasConcept C2779036427 @default.
- W4313597902 hasConcept C2779161974 @default.
- W4313597902 hasConcept C2779548226 @default.
- W4313597902 hasConcept C2780306776 @default.
- W4313597902 hasConcept C71924100 @default.
- W4313597902 hasConcept C90924648 @default.
- W4313597902 hasConceptScore W4313597902C126322002 @default.
- W4313597902 hasConceptScore W4313597902C159641895 @default.
- W4313597902 hasConceptScore W4313597902C2776301958 @default.
- W4313597902 hasConceptScore W4313597902C2776914184 @default.
- W4313597902 hasConceptScore W4313597902C2777628954 @default.
- W4313597902 hasConceptScore W4313597902C2778213512 @default.
- W4313597902 hasConceptScore W4313597902C2778661090 @default.
- W4313597902 hasConceptScore W4313597902C2779036427 @default.
- W4313597902 hasConceptScore W4313597902C2779161974 @default.
- W4313597902 hasConceptScore W4313597902C2779548226 @default.
- W4313597902 hasConceptScore W4313597902C2780306776 @default.
- W4313597902 hasConceptScore W4313597902C71924100 @default.
- W4313597902 hasConceptScore W4313597902C90924648 @default.
- W4313597902 hasIssue "2" @default.
- W4313597902 hasLocation W43135979021 @default.
- W4313597902 hasLocation W43135979022 @default.
- W4313597902 hasOpenAccess W4313597902 @default.
- W4313597902 hasPrimaryLocation W43135979021 @default.
- W4313597902 hasRelatedWork W1020137194 @default.
- W4313597902 hasRelatedWork W1911631926 @default.
- W4313597902 hasRelatedWork W1983884646 @default.
- W4313597902 hasRelatedWork W2029894551 @default.
- W4313597902 hasRelatedWork W2047016359 @default.
- W4313597902 hasRelatedWork W2051536597 @default.
- W4313597902 hasRelatedWork W2322441760 @default.
- W4313597902 hasRelatedWork W2335730662 @default.
- W4313597902 hasRelatedWork W2382476504 @default.
- W4313597902 hasRelatedWork W2607916424 @default.
- W4313597902 hasVolume "81" @default.
- W4313597902 isParatext "false" @default.
- W4313597902 isRetracted "false" @default.
- W4313597902 workType "article" @default.